Terms: = Lymphoma AND KIF5B, ENSG00000170759, 3799, P33176, UKHC, KNS1, KNS, KINH AND Treatment
13 results:
1. Multisystem ALK-positive histiocytosis: a multi-case study and literature review.
Liu W; Liu HJ; Wang WY; Tang Y; Zhao S; Zhang WY; Yan JQ; Liu WP
Orphanet J Rare Dis; 2023 Mar; 18(1):53. PubMed ID: 36915094
[TBL] [Abstract] [Full Text] [Related]
2. ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via
Chuang TP; Lai WY; Gabre JL; Lind DE; Umapathy G; Bokhari AA; Bergman B; Kristenson L; Thorén FB; Le A; Doebele RC; Van den Eynden J; Palmer RH; Hallberg B
Proc Natl Acad Sci U S A; 2023 Feb; 120(8):e2216479120. PubMed ID: 36791109
[TBL] [Abstract] [Full Text] [Related]
3. ALK Translocation in ALK-Positive Mesenchymal Tumors: Diagnostic and Therapeutic Insights.
Jung M; Moon KC; Bae J; Kim TM; Kim M; Jeon YK; Lee C
Arch Pathol Lab Med; 2022 Dec; 146(12):1460-1470. PubMed ID: 35438749
[TBL] [Abstract] [Full Text] [Related]
4. ALK-positive histiocytosis with disseminated disease responded to alectinib: a case report.
Tian Y; Li J; Liu B; Xie H; Zheng M; Yao W
Ann Palliat Med; 2021 Sep; 10(9):10095-10101. PubMed ID: 34628929
[TBL] [Abstract] [Full Text] [Related]
5. A rare kif5b-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.
Zeng H; Liu Y; Wang W; Tang Y; Tian P; Li W
Ann Palliat Med; 2021 Jul; 10(7):8352-8357. PubMed ID: 33832282
[TBL] [Abstract] [Full Text] [Related]
6. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
Feng T; Chen Z; Gu J; Wang Y; Zhang J; Min L
Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
[TBL] [Abstract] [Full Text] [Related]
7. Clinical Utility of Cell-Free DNA for the Detection of
McCoach CE; Blakely CM; Banks KC; Levy B; Chue BM; Raymond VM; Le AT; Lee CE; Diaz J; Waqar SN; Purcell WT; Aisner DL; Davies KD; Lanman RB; Shaw AT; Doebele RC
Clin Cancer Res; 2018 Jun; 24(12):2758-2770. PubMed ID: 29599410
[No Abstract] [Full Text] [Related]
8. Expression and copy number gains of the RET gene in 631 early and mid stage non-small cell lung cancer cases.
Tan L; Hu Y; Tao Y; Wang B; Xiao J; Tang Z; Lu T; Tang H
Thorac Cancer; 2018 Apr; 9(4):445-451. PubMed ID: 29473341
[TBL] [Abstract] [Full Text] [Related]
9. Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.
Rosenbaum JN; Bloom R; Forys JT; Hiken J; Armstrong JR; Branson J; McNulty S; Velu PD; Pepin K; Abel H; Cottrell CE; Pfeifer JD; Kulkarni S; Govindan R; Konnick EQ; Lockwood CM; Duncavage EJ
Mod Pathol; 2018 May; 31(5):791-808. PubMed ID: 29327716
[TBL] [Abstract] [Full Text] [Related]
10. Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients.
Plenker D; Bertrand M; de Langen AJ; Riedel R; Lorenz C; Scheel AH; Müller J; Brägelmann J; Daßler-Plenker J; Kobe C; Persigehl T; Kluge A; Wurdinger T; Schellen P; Hartmann G; Zacherle T; Menon R; Thunnissen E; Büttner R; Griesinger F; Wolf J; Heukamp L; Sos ML; Heuckmann JM
Clin Cancer Res; 2018 Mar; 24(6):1337-1343. PubMed ID: 29284707
[No Abstract] [Full Text] [Related]
11. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H
Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307
[TBL] [Abstract] [Full Text] [Related]
12. Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm.
Menezes J; Acquadro F; Wiseman M; Gómez-López G; Salgado RN; Talavera-Casañas JG; Buño I; Cervera JV; Montes-Moreno S; Hernández-Rivas JM; Ayala R; Calasanz MJ; Larrayoz MJ; Brichs LF; Gonzalez-Vicent M; Pisano DG; Piris MA; Álvarez S; Cigudosa JC
Leukemia; 2014 Apr; 28(4):823-9. PubMed ID: 24072100
[TBL] [Abstract] [Full Text] [Related]
13. Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.
Tiseo M; Gelsomino F; Bartolotti M; Bordi P; Bersanelli M; Rossi G; Ardizzoni A
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1677-87. PubMed ID: 22050016
[TBL] [Abstract] [Full Text] [Related]
